Dr Tan Min-Han, founder and CEO of Lucence Diagnostics, which has pioneered a liquid biopsy to easily detect nasopharyngeal cancer by examining a patient's blood. Through zooming in on a DNA fragment of the cancer-causing Epstein-Barr virus called BamHI-W
Caption: 
Dr Tan Min-Han, founder and CEO of Lucence Diagnostics, which has pioneered a liquid biopsy to easily detect nasopharyngeal cancer by examining a patient's blood. Through zooming in on a DNA fragment of the cancer-causing Epstein-Barr virus called BamHI-W, the liquid biopsy is 97 per cent accurate in telling if a patient has nasopharyngeal cancer or not.
Credits: 
PHOTO: DON WONG FOR THE STRAITS TIMES